(IN BRIEF) Novartis will present data from 15 abstracts across its kidney disease portfolio at the European Renal Association Congress 2026 in Glasgow from June 3 to 6. The presentations include late-breaking Phase III data for Vanrafia® from the ALIGN … Read the full press release
Posted in Business, Financial, Healthcare, Investment, Marketing, Pharma & Biotech, Switzerland
Tagged 124-week data, ADPKD, ALIGN trial, anti-APRIL therapy, anti-miR-17 oligonucleotide, APPLAUSE-IgAN, APPRISE-C3G, atrasentan, autosomal dominant polycystic kidney disease, Basel, C3 glomerulopathy, C3G, C3G and ADPKD Data at European Renal Association Congress, cardiovascular renal and metabolic development, dialysis, EGFR, ERA 2026, European Renal Association Congress, Fabhalta, farabursen, Glasgow, IgA nephropathy, IgAN, IgNITE, immune-mediated kidney diseases, iptacopan, June 2026, kidney care, kidney disease, kidney function, late-breaking data, Novartis, Novartis Advances Kidney Disease Research with New IgAN, Novartis Highlights Expanding Renal Pipeline and Disease Insights at ERA 2026 in Glasgow, Novartis Presents New Evidence Supporting Future Treatment Approaches in IgA Nephropathy and C3 Glomerulopathy, Novartis Strengthens Kidney Care Portfolio with New Scientific Data Across Progressive Immune-Mediated Renal Diseases, Novartis to Showcase Phase III Vanrafia and Fabhalta Data Alongside Long-Term Zigakibart Results at ERA 2026, phase I/II data, Phase III data, real-world evidence, renal disease, renal portfolio, Ruchira Glaser, transplantation, Vanrafia, zigakibart
(IN BRIEF) Roche presented positive phase I/II data for NXT007, its Chugai-engineered bispecific antibody for haemophilia A, at the 2025 ISTH Congress. In the NXTAGE study’s highest-dose cohorts (B-3 and B-4), none of the 30 participants experienced bleeds requiring treatment, … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Security & Safety, Switzerland, Technology
Tagged bispecific antibody, Chugai, clinical development, emicizumab, global supply chain, Haemophilia A, haemostatic normalisation, Hemlibra, ISTH Congress 2025, Levi Garraway, NXT007, NXTAGE study, phase I/II data, Roche, subcutaneous dosing, thromboembolic events
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?